Leveraging Machine Learning Models and Pharmacy Refill Adherence as a Cost-Effective Proxy for Predicting HIV Viral Suppression during Antiretroviral Therapy in Resource-Limited Settings

Abstract Introduction Achieving viral suppression is central to HIV epidemic control; however, routine viral load (VL) testing in many low- and middle-income countries is constrained by laboratory capacity, logistics, and cost. In Tanzania, disparities in VL coverage persist across age groups and geographical regions, limiting the timely detection of treatment failure. Pharmacy refill adherence is a low-cost, routinely collected objective indicator of treatment behavior. This study assessed whether pharmacy refill adherence, enhanced using machine learning (ML) models, can reliably predict viral suppression among people living with HIV (PLHIV) in Tanzania. Methods We conducted a retrospective analysis using nationally representative patient-level data from the Care and Treatment Center (CTC-2) database, collected between 2017 and 2021. A random sample of 40,000 records was drawn, of which 28,044 patients met the inclusion criteria. Pharmacy refill adherence was calculated as the proportion of days covered and capped at 100%. Viral suppression was defined as a VL of 0.85), followed by Gradient Boosting Machines and Random Forest, while logistic regression provided stable baseline estimates. Pharmacy refill adherence, duration of follow-up, clinic visit frequency, and patient age were the strongest predictors of viral suppression. Conclusion Pharmacy refill adherence is a strong predictor of viral suppression and provides a feasible and cost-effective tool for monitoring ART outcomes in settings with limited VL testing. Machine learning approaches further enhance the predictive value of routine program data and can support the early identification of patients at risk of virological failure. Integrating adherence-based predictive analytics into national HIV program monitoring systems may strengthen differentiated service delivery, improve treatment outcomes, and accelerate progress toward the UNAIDS 95–95–95 targets in Tanzania and similar resource-limited settings.